Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Triiodothyronine (T3) in Ischemic Heart Failure
NCT05384847Phase 1Completed
- Sponsor
- Emory University
- Start
- Dec 2022
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of liothyronine in heart failure (HF) (3 arms), sponsored by Emory University. Primary endpoints: Changes in the presence of clinical arrhythmias at 12 months and The number of participants with Angina, acute coronary syndrome, death during the first week at 1 week. Started Dec 2022; status: completed.
02
Drugs
liothyronine
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT05384847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05384847.